Status:
UNKNOWN
Predictive Factors for Response to New Oral Anticoagulants in the Treatment of Non-valvular Atrial Fibrillation..
Lead Sponsor:
Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Conditions:
Atrial Fibrillation
Eligibility:
All Genders
18-100 years
Brief Summary
Post-authorization observational, prospective, follow-up study of a cohort of patients with non-valvular atrial fibrillation who are treated with direct oral anticoagulants (DOACs) to evaluate the cli...
Detailed Description
Post-authorization observational, prospective, follow-up study of a cohort of patients with non-valvular atrial fibrillation treated with direct oral anticoagulants (dabigatran, rivaroxaban, apixaban ...
Eligibility Criteria
Inclusion
- Men or women over 18 years of age
- Patients with non-valvular atrial fibrillation (NVAF).
- Patients who are going to receive or are receiving treatment with any of the DOACs (dabigatran, rivaroxaban, apixaban or edoxaban) for the prevention of stroke and systemic embolism in adult patients with NVAF, according to the drug label.
- Patients who agree to participate in the study and give their written consent.
Exclusion
- Patients on treatment with other anticoagulants.
- Patients suffering from a malignant or terminal disease whose life expectancy is less than 6 months.
Key Trial Info
Start Date :
June 18 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 30 2023
Estimated Enrollment :
700 Patients enrolled
Trial Details
Trial ID
NCT04297150
Start Date
June 18 2020
End Date
September 30 2023
Last Update
June 6 2023
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Universitario de Burgos
Burgos, Spain, 09006
2
Hospital Universitario de La Princesa
Madrid, Spain, 28006
3
Hospital Gómez Ulla
Madrid, Spain, 28028
4
Hospital Universitario Ramón y Cajal
Madrid, Spain, 28034